Core Viewpoint - Hangzhou Anxu Biotechnology Co., Ltd. has demonstrated operational resilience amid challenges in the in vitro diagnostics (IVD) industry, including intensified centralized procurement and changes in the international trade environment, by actively adjusting its market strategies [1][3]. Financial Performance - In the first half of 2025, the company reported revenue of 230 million yuan and a net profit of 23.5862 million yuan after deducting non-recurring items [1]. Market Strategy - The company has adopted a "dual-wheel drive" strategy focusing on both international and domestic markets to address uncertainties in overseas markets, leading to a strong adaptability in overall operations despite performance fluctuations [1][3]. - In the domestic market, Anxu Biotechnology successfully obtained multiple medical device registration certificates, including for respiratory virus antigen detection and influenza virus antigen testing kits, targeting essential healthcare needs [1][2]. Business Expansion - The company has developed a dual-track model of "deepening B-end and breaking into C-end" by leveraging the "Anxu Ke" brand to expand into e-commerce, resulting in steady sales growth in home health management products [2]. - Anxu Biotechnology has established a "global network + localized service" system to strengthen its presence in traditional markets such as Europe, Oceania, Asia, and Africa, while also extending into emerging markets to mitigate single-market risks [2]. Diversification - The company is actively expanding into new fields while consolidating its traditional advantages in point-of-care testing (POCT). Its subsidiary, Taimengle, focuses on pet medical testing, developing over a hundred testing solutions for various infectious diseases and health monitoring [2]. - The company has launched the GluMate chronic disease management app, integrating existing POCT products into a comprehensive solution that includes hardware, software, and data services [2]. Industry Outlook - The global IVD market is projected to grow from $109.2 billion in 2024 to $135.1 billion by 2029, with strong growth expected in microfluidic technology and pet medical testing segments [3]. - Despite the overall pressure on the industry in the first half of 2025, the company has shown innovative vitality and resilience through its integrated supply chain, global layout, and diversified business strategies, laying a solid foundation for long-term healthy development [3].

Core Viewpoint - Anxu Bio maintains operational resilience amid challenges in the in vitro diagnostic (IVD) industry, reporting a slight revenue decline but significant profit growth in the first half of 2025 [1][2][3] Group 1: Financial Performance - The company's revenue for the first half of 2025 was 230 million yuan, a year-on-year decrease of 7.42% [1] - The net profit excluding non-recurring items reached 24 million yuan, reflecting a year-on-year increase of 24.89% [1] Group 2: Market Strategy - Anxu Bio has adopted a "dual-wheel drive" strategy focusing on both domestic and international markets to counteract external uncertainties, such as delayed customer orders due to tariffs [1][2] - The company has successfully registered multiple medical device certifications, enhancing its product offerings in critical areas like infectious disease prevention and cardiovascular emergencies [1] Group 3: Business Expansion - The launch of the "Anxu Ke" brand has allowed the company to penetrate the C-end market through e-commerce, establishing a dual-track model of deepening B-end and breaking into C-end markets [2] - Anxu Bio is expanding its presence in the pet medical testing sector through its subsidiary, targeting a market projected to reach 84.1 billion yuan in 2024, growing at 5.6% [2] Group 4: Future Outlook - The global IVD market is expected to grow from 109.2 billion USD in 2024 to 135.1 billion USD by 2029, with strong growth in microfluidic technology and pet medical testing [3] - Anxu Bio's strategy aligns with industry trends by focusing on a diversified product matrix and expanding both domestic and international markets, positioning itself for long-term growth [3]

Core Viewpoint - The company, Hangzhou Anxu Biotechnology Co., Ltd., has released its 2025 semi-annual report, which includes details on its financial status, operational results, and future development plans [1][7]. Group 1: Company Overview - The company is identified by the stock code 688075 and is referred to as Anxu Biotechnology [1]. - The report emphasizes the importance of reading the full semi-annual report for a comprehensive understanding of the company's performance and future plans [1]. Group 2: Financial Data - The total amount of funds raised through the public offering was RMB 1,200.30 million, with a net amount of RMB 1,055.85 million after deducting various fees [12]. - As of June 30, 2025, the balance of raised funds was RMB 27.59 million [13]. Group 3: Fund Management - The company has established a management system for the raised funds, ensuring that they are stored in designated special accounts and used according to regulations [14]. - The company has signed tripartite supervision agreements with banks to ensure proper management of the raised funds [15][16]. Group 4: Fund Usage - The company has completed several projects, reallocating surplus funds to new projects, including the "Technical R&D Headquarters Construction Project" with a planned investment of RMB 292.45 million [32][34]. - The company has not used idle raised funds to temporarily supplement working capital as of the reporting period [20]. Group 5: Compliance and Reporting - The company has complied with all relevant regulations regarding the management and use of raised funds, ensuring timely and accurate disclosures [35].

证券代码：688075 证券简称：安旭生物 公告编号：2025-023 杭州安旭生物科技股份有限公司 第二届监事会第十七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"）第二 届监事会第十七次会议通知于 2025 年 8 月 8 日以邮件方式发出送达全体监事，会 议于 2025 年 8 月 18 日以现场方式召开，会议由公司监事会主席张炯先生主持， 会议应到监事 3 人，实到监事 3 人。公司董事会秘书列席会议。本次会议的召集、 召开符合《中华人民共和国公司法》等法律、法规、规章、规范性文件和《公司 章程》的有关规定，会议形成的决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于 2025 年半年度报告全文及其摘要的议案》 根据《证券法》《公开发行证券的公司信息披露内容与格式准则第 3 号——半 年度报告的内容与格式》《上海证券交易所科创板股票上市规则》等规则要求，我 们在全面审阅公司 2025 年半年度报告后，发 ...

杭州安旭生物科技股份有限公司 2025 年半年度报告 公司代码：688075 公司简称：安旭生物 杭州安旭生物科技股份有限公司 2025 年半年度报告 1 / 144 杭州安旭生物科技股份有限公司 2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告"第三节 管理层讨论与分析"之"四、风险因素"中说明了可能对公司产生重大 不利影响的风险因素，敬请投资者注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人凌世生、主管会计工作负责人康敏及会计机构负责人（会计主管人员）康敏声 明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告所涉及的公司未来计划、经营计划、发展战略等前瞻性陈述，不构成公司对投资者的实质 承诺，请投 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-024 杭州安旭生物科技股份有限公司 关于 2025 年半年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管要求》 《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》等相关业务 规则的规定，杭州安旭生物科技股份有限公司（以下简称"安旭生物"或"公司"） 董事会编制了《关于 2025 年半年度募集资金存放与实际使用情况的专项报告》。 具体如下： 截至 2025 年 6 月 30 日，公司募集资金余额为 27,585,733.85 元，具体情况如下： 单位：人民币元 | 项目 | 金额 | | | --- | --- | --- | | 募集资金净额 | | 1,055,846,296.20 | 1 | 减：直接投入募投项目 | 578,396,111.43 | | --- | --- | | 募投项目结项补充流动资金 | 47,100,230 ...

杭州安旭生物科技股份有限公司 关于公司 2025 年度提质增效重回报专项行动方案的 半年度评估报告 杭州安旭生物科技股份有限公司（以下简称"安旭生物、公司"）为提高上 市公司质量，增强投资者回报，提升投资者的获得感，维护公司全体股东利益， 基于对公司未来发展前景的信心以及对公司价值的认可，公司于 2025 年 4 月 30 日发布了《关于 2025 年度"提质增效重回报"行动方案的公告》。公司根据行 动方案内容，积极开展和落实各项工作，现将 2025 年上半年的主要工作成果报 告如下： 一、 聚焦主营业务，提升科技创新能力 公司是一家专注于 POCT 试剂及仪器的研发、生产与销售的高科技企业。公 司拥有生物原料、免疫层析、干式生化、化学发光、精准检测、液态生物芯片、 微流控、临床检验仪器等几大技术平台。发展形成了覆盖毒品检测、传染病检测、 慢性病检测、妊娠检测、肿瘤检测、心肌检测、生化检测、过敏原检测八大领域 的 POCT 试剂，已形成原料、试剂、仪器三位一体的产业链布局。产品畅销欧美、 澳洲、亚洲等 150 多个国家和地区。现已成为国内少数几家在 POCT 国际市场能 够与跨国体外诊断行业巨头竞争的中国体外 ...

智通财经APP讯，安旭生物(688075.SH)发布2025年半年度报告，报告期内，公司实现营业收入2.3亿 元，同比下降7.42%。实现归属于上市公司股东的净利润5930.59万元，同比下降48.57%。实现归属于上 市公司股东的扣除非经常性损益的净利润2358.62万元，同比增长24.85%。基本每股收益0.47元。 ...

Core Viewpoint - The company is holding its first extraordinary general meeting of shareholders in 2025 to discuss several key proposals, including the cancellation of the supervisory board, cash management using idle funds, and the election of a new board of directors [1][7][9]. Group 1: Meeting Proposals - Proposal 1 involves the cancellation of the supervisory board and amendments to the company's articles of association, with the supervisory board's powers being transferred to the audit committee of the board of directors [7][8]. - Proposal 2 seeks approval to use up to RMB 4 billion of temporarily idle funds for cash management, focusing on safe and liquid investment products [8][9]. - Proposal 3 is for the election of three non-independent directors to the third board of directors, with candidates nominated for the positions [9][10]. - Proposal 4 involves the election of three independent directors to the third board of directors, with candidates also nominated for these positions [11][12]. Group 2: Meeting Procedures - The meeting will be conducted with both on-site and online voting, with specific time slots for voting outlined [4][5]. - Shareholders must register and provide identification to participate, and only registered attendees can vote on-site [2][3]. - The meeting will follow a structured agenda, including the introduction of attendees, discussion of proposals, and voting [6][8].

杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会会议资料 杭 州 安 旭 生 物 科 技 股 份 有 限 公 司 2025 年第一次临时股东大会会议资料 股票简称：安旭生物 股票代码：688075 2025 年 8 月 22 日 1 杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 2025 年第一次临时股东大会须知………………………………………………………..………3 | | --- | | 年第一次临时股东大会议程…………………………………………………………..… 5 2025 | | 议案一：关于取消监事会、修订<公司章程>并办理工商变更登记及修订相关制度的议案…7 | | 议案二：关于使用部分暂时闲置自有资金进行现金管理的议案………………………….…..8 | | 议案三：关于董事会换届选举暨选举第三届董事会非独立董事的议案………………………9 | | 议案四：关于董事会换届选举暨选举第三届董事会独立董事的议案………………….….…10 | 2 杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会会议资料 2025 年第一次临时股东大会须知 为了维护 ...